• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ANI Pharmaceuticals (ANIP) Heads To Investor Conferences, Is It 35% Undervalued?

    Simply Wall St·09/17/2026 00:27:12
    Listen to the news

    ANI Pharmaceuticals conferences put the spotlight on investor messaging

    ANI Pharmaceuticals (ANIP) is set to feature at three healthcare investment conferences in September 2026, giving management multiple platforms to refresh its story for institutional investors and prospective shareholders.

    Recent trading has been mixed. The share price is at US$73.59 after a 1-day share price return of 2.05% and a 7-day gain of 4.09%. However, the 90-day share price return is down 7.42%, and the 1-year total shareholder return has declined 22.83%, even though the 5-year total shareholder return of 144.57% still points to a very different long-term journey for ANI Pharmaceuticals.

    Scan beyond ANI Pharmaceuticals and compare other healthcare stocks with mixed momentum using our hand picked 33 high quality undervalued stocks as a starting universe.

    ANI Pharmaceuticals looks like a solid operator on paper, yet the share price has retreated over the past year. So are you looking at a quality business on sale, or one already fairly valued?

    Most Popular Narrative: 35% Undervalued

    Against a fair value estimate of $112.71, ANI Pharmaceuticals at $73.59 screens as heavily discounted. That gap is anchored in a specific growth story rather than just market mood.

    There is significant, untapped growth potential for Cortrophin Gel across core and emerging indications (neurology, nephrology, rheumatology, pulmonology, ophthalmology, and gout). Patient populations are far below prior peaks, and epidemiological data suggests the addressable market could be several times larger due to an aging population and the rising prevalence of chronic diseases. Strong execution and investment in the Rare Disease business, including expansion of the sales force, improved convenience with the prefilled syringe, and successful new product launches, are accelerating patient adoption and driving a more favorable revenue mix. This is raising net margins and overall EBITDA.

    See why 4 investors see ANI Pharmaceuticals as 35% undervalued.

    The most followed narrative applies a 7.11% discount rate and lands on that $112.71 figure. Analysts expect revenue growth and a higher profit margin profile over time to justify it. That framework sits alongside a consensus price target of $108.38, which is above the current share price but below the narrative fair value, showing how different valuation lenses are being used on ANI Pharmaceuticals.

    Result: Fair Value of $112.71 (UNDERVALUED)

    Still, the bullish ANI Pharmaceuticals story can unravel if payers clamp down on Cortrophin Gel reimbursement or if key generic exclusivities fade faster than expected.

    Find out about the key risks to this ANI Pharmaceuticals narrative.

    Next Steps

    Mixed signals or a clear opportunity for ANI Pharmaceuticals: either way, the clock is ticking for you to weigh the upside against the downside. To see how the positives stack up against the drawbacks in one place, review the 4 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond ANI Pharmaceuticals?

    If ANI Pharmaceuticals has sparked your interest, do not stop here. Put a few more quality candidates on your watchlist using the Simply Wall St Screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.